Post-IPO Equity Funded Health Care Startups
Among post-IPO equity rounds in this Health Care list, the largest disclosed amount is Hyperfine’s $126M (2021-12-23).
Among post-IPO equity rounds in this Health Care list, the largest disclosed amount is Hyperfine’s $126M (2021-12-23). The next-highest disclosed rounds sit close by but far below that peak—Ambulnz at $125M (2021-11-08) and Axonics Modulation Technologies at $112M (2022-08-02)—while several disclosed rounds cluster under $50M (for example, CARMAT at $44M on 2022-04-12 and Tricida at $42M on 2021-11-15). Another outlier pattern shows up at the low end: the smallest disclosed amount is ChemoTech’s $100K (2022-03-09), with multiple $1M rounds nearby (CareSpan Health 2022-04-13; CareMax 2022-01-06; IMAC Holdings 2022-05-19; Nephros 2021-07-13; Sixth Wave Innovations 2021-12-17).
Geographically, the dataset is mostly U.S./Canada/Europe rather than a single U.S. metro: Vancouver, British Columbia appears twice (Taat Global on 2022-06-01 and WELL Health Technologies on 2022-05-19), while the rest of the U.S. entries are split across multiple cities (e.g., Menlo Park for Tricida on 2021-11-15; Guilford for Hyperfine on 2021-12-23). Temporally, rounds span 2021-07-01 (Pulse Biosciences) through 2022-10-19 (Fresenius AG), with the most recent 90-day window dominated by 2022-08 to 2022-10 closings such as Axonics Modulation Technologies ($112M on 2022-08-02), Assure Neuromonitoring ($6M on 2022-08-22), and Silk Road Medical ($100M on 2022-10-18). Out of 22 rows, 2 amounts are undisclosed (Fresenius AG on 2022-10-19 and C4 Therapeutics on 2022-08-15).
Most recent rounds
22 shownRelated listings
Frequently asked
What is the largest disclosed post-IPO equity round here, and how clearly does it separate from the rest?
Hyperfine’s $126M (2021-12-23) is the top disclosed amount. The next-largest disclosed rounds—Ambulnz’s $125M (2021-11-08) and Axonics Modulation Technologies’ $112M (2022-08-02)—are close in absolute dollars but still below the $126M peak, and several other disclosed rounds fall into the $40M–$50M range (e.g., Tricida $42M on 2021-11-15; CARMAT $44M on 2022-04-12).
Are there small-round clusters near the bottom of disclosed amounts, or just one-off low deals?
The low end includes ChemoTech’s $100K (2022-03-09) as a clear floor among disclosed figures. Beyond that extreme, a cluster of $1M rounds appears across multiple companies and dates—IMAC Holdings ($1M on 2022-05-19), CareSpan Health ($1M on 2022-04-13), CareMax ($1M on 2022-01-06), Sixth Wave Innovations ($1M on 2021-12-17), and Nephros ($1M on 2021-07-13).
Where do rounds concentrate geographically—does one city or country dominate?
Vancouver, British Columbia is the only repeated city in the list, with two entries: WELL Health Technologies ($35M on 2022-05-19) and Taat Global ($2M on 2022-06-01). Outside that, the U.S. entries are distributed across different cities rather than a single hub—for example Hyperfine in Guilford (2021-12-23), Tricida in Menlo Park (2021-11-15), and Ambulnz in New York (2021-11-08).
Which part of the timeline is most crowded in these 22 rows?
Most of the high-dollar and mid-dollar disclosed rounds in this slice fall from August through October 2022, including Axonics Modulation Technologies ($112M on 2022-08-02), Assure Neuromonitoring ($6M on 2022-08-22), and Silk Road Medical ($100M on 2022-10-18). The earliest row shown is 2021-07-01 (Pulse Biosciences; $50M), while the latest is 2022-10-19 (Fresenius AG; amount undisclosed).
How often are amounts undisclosed, and does that affect any outlier comparisons?
Undisclosed amounts appear in 2 of 22 rows: Fresenius AG on 2022-10-19 and C4 Therapeutics on 2022-08-15. Because the largest and smallest comparisons rely on disclosed figures, Hyperfine’s $126M (2021-12-23) remains the top disclosed amount, while ChemoTech’s $100K (2022-03-09) remains the smallest disclosed amount.
Are there multiple very large rounds in the same approximate value band, rather than one-off peaks?
Yes. There are several disclosed rounds in the ~$110M–$125M band: Ambulnz at $125M (2021-11-08), Hyperfine at $126M (2021-12-23), and Axonics Modulation Technologies at $112M (2022-08-02). That concentration contrasts with the frequent sub-$50M outcomes elsewhere in the list, such as ImmunityBio at $11M (2022-07-22) and Accelerate Diagnostics at $4M (2022-04-07).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.